Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Squamous Non-Small Cell Lung Cancer sqNSCLC Clear all
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Squamous Tumors
Interventions
ABBV-711, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 11:47 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation
Interventions
sapanisertib
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Davis, California • Santa Rosa, California • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced May 21, 2026, 11:47 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC
Interventions
Part A: AZD8186 monotherapy, Part B: AZD8186 monotherapy, Part C1: Abiraterone acetate combination with AZD8186, Part D1: AZD2014 combination with AZD8186, Part D2 AZD2014 combination with AZD8186, Part C2: Abiraterone acetate combination with AZD8186
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced May 21, 2026, 11:47 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Squamous-Cell Non-Small-Cell Lung Cancer
Interventions
Bemarituzumab, Docetaxel, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Orange, California • Morristown, New Jersey • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced May 21, 2026, 11:47 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions
tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
124
States / cities
Encinitas, California • La Jolla, California • Sacramento, California + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 11:47 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Squamous NSCLC
Interventions
CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg
Biological
Lead sponsor
CureVac
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Fairfax, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced May 21, 2026, 11:47 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions
VLS-1488
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced May 21, 2026, 11:47 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Squamous Non-Small Cell Lung Carcinoma
Interventions
Pacliltaxel or Nab-paclitaxel, Carboplatin or Cisplatin, Pembrolizumab, Cabozantinib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 21, 2026, 11:47 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
iO Resistant sqNSCLC
Interventions
IBI363, Control Arm
Drug
Lead sponsor
Fortvita Biologics (USA)Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Jonesboro, Arkansas • Fountain Valley, California • Los Alamitos, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 11:47 PM EDT